The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630
Open accessAbstract
We have tested our prediction that AM630 is a CB 2 cannabinoid receptor ligand and also investigated whether L759633 and L759656, are CB 2 receptor agonists. Binding assays with membranes from CHO cells stably transfected with human CB 1 or CB 2 receptors using [3 H]‐CP55940, confirmed the CB 2‐selectivity of L759633 and L759656 (CB 2/CB 1 affinity ratios=163 and 414 respectively) and showed AM630 to have a Ki at CB 2 receptors of 31.2 n M and a CB 2/CB 1 affinity ratio of 165. In CB 2‐transfected cells, L759633 and L759656 were potent inhibitors of forskolin‐stimulated cyclic AMP production, with EC 50 values of 8.1 and 3.1 n M respectively and CB 1/CB 2 EC 50 ratios of >1000 and >3000 respectively. AM630 inhibited [35 S]‐GTPγS binding to CB 2 receptor membranes (EC 50=76.6 n M), enhanced forskolin‐stimulated cyclic AMP production in CB 2‐transfected cells (5.2 fold by 1 μ M), and antagonized the inhibition of forskolin‐stimulated cyclic AMP production in this cell line induced by CP55940. In CB 1‐transfected cells, forskolin‐stimulated cyclic AMP production was significantly inhibited by AM630 (22.6% at 1 μ M and 45.9% at 10 μ M) and by L759633 at 10 μ M (48%) but not 1 μ M. L759656 (10 μ M) was not inhibitory. AM630 also produced a slight decrease in the mean inhibitory effect of CP55940 on cyclic AMP production which was not statistically significant. We conclude that AM630 is a CB 2‐selective ligand that behaves as an inverse agonist at CB 2 receptors and as a weak partial agonist at CB 1 receptors. L759633 and L759656 are both potent CB 2‐selective agonists. British Journal of Pharmacology (1999) 126, 665–672; doi:10.1038/sj.bjp.0702351
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“…for AM630 in these experiments with CB2-transfected cell membranes (31.2 nM) is similar to a previously reported Ki value of AM630 (11.2 nM) for displacement of [3H]-CP55940 from a membrane preparation of mouse spleen (Pertwee, 1998), a tissue known to express CB2 receptors (Munro et al., 1993).”
ResultInfluentialPharmacology of cannabinoid CB1 and CB2 receptors
Pertwee, R. G. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82001-3 · Cited by 1,470
Self-citationBisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Di Marzo, V. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,311
Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L., & Mitchell, R. L. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10492-6 · Cited by 869
SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor
Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J.-M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37266-0 · Cited by 709
Colquhoun, D. (1971) · UCL Discovery (University College London) · Cited by 698
Glass, M., & Felder, C. C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-14-05327.1997 · Cited by 635
Showalter, V. M., Compton, D. R., Martin, B. R., & Abood, M. E. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20744-3 · Cited by 571
Pasternack, B. S., & Colquhoun, D. (1972) · Journal of the American Statistical Association · doi:10.2307/2284489 · Cited by 547
Cited by
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Self-citationThe Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., et al. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003004 · Cited by 1,605
Self-citationThe endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Lo Verme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calignano, A., & Piomelli, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006353 · Cited by 882
Di, S., Malcher-Lopes, R., Halmos, K. C., & Tasker, J. G. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-12-04850.2003 · Cited by 801
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 756
Self-citationCB2: a cannabinoid receptor with an identity crisis
Atwood, B. K., & Mackie, K. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00729.x · Cited by 619
Pharmacological Actions of Cannabinoids
Pertwee, R. G. (2005) · Handbook of Experimental Pharmacology · doi:10.1007/3-540-26573-2_1 · Cited by 597
Self-citationThe CB2 receptor and its role as a regulator of inflammation
Turcotte, C., Blanchet, M.-R., Laviolette, M., & Flamand, N. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2300-4 · Cited by 588
HU-308: A specific agonist for CB 2 , a peripheral cannabinoid receptor
Hanuš, L., Breuer, A., Tchilibon, S., Shiloah, S., Goldenberg, D., Horowitz, M., Pertwee, R. G., Ross, R. A., Mechoulam, R., & Fride, E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14228 · Cited by 571
Self-citationCannabinoid receptors and their ligands
Pertwee, R. G., & Ross, R. A. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0341 · Cited by 561
Self-citationThe Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Ibrahim, M. M., Porreca, F., Lai, J., Albrecht, P. J., Rice, F. L., Khodorova, A., Davar, G., Makriyannis, A., Vanderah, T. W., Mata, H. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409888102 · Cited by 521
Self-citationIbrahim, M. M., Deng, H., Zvonok, A., Cockayne, D. A., Kwan, J., Mata, H. P., Vanderah, T. W., Lai, J., Porreca, F., Makriyannis, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834309100 · Cited by 491
Self-citationSVIZENSKA, I., DUBOVY, P., & SULCOVA, A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.05.010 · Cited by 457
Guindon, J., & Hohmann, A. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707531 · Cited by 423
The endocannabinoid system as a target for therapeutic drugs
Piomelli, D., Giuffrida, A., Calignano, A., & Rodrı́guez de Fonseca, F. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01482-6 · Cited by 421
CB2 cannabinoid receptor-mediated peripheral antinociception
Malan, P. T., Ibrahim, M. M., Deng, H., Liu, Q., Mata, H. P., Vanderah, T., Porreca, F., & Makriyannis, A. (2001) · Pain · doi:10.1016/s0304-3959(01)00321-9 · Cited by 391
Self-citationThe Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications
Lambert, D. M., & Fowler, C. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058183t · Cited by 350
Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures
Hua, T., Li, X., Wu, L., Iliopoulos-Tsoutsouvas, C., Wang, Y., Wu, M., Shen, L., Brust, C. A., Nikas, S. P., Song, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.008 · Cited by 337
Self-citationLigands that target cannabinoid receptors in the brain: from THC to anandamide and beyond
Pertwee, R. G. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00108.x · Cited by 314
Self-citationWright, K. L., Duncan, M., & Sharkey, K. A. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707486 · Cited by 264
Rock, E., Bolognini, D., Limebeer, C., Cascio, M., Anavi‐Goffer, S., Fletcher, P., Mechoulam, R., Pertwee, R., & Parker, L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01621.x · Cited by 255
Self-citationTherapeutic potential of cannabis-related drugs
Alexander, S. P. H. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.07.001 · Cited by 149
Yao, B. B., Hsieh, G. C., Frost, J. M., Fan, Y., Garrison, T. R., Daza, A. V., Grayson, G. K., Zhu, C. Z., Pai, M., Chandran, P., et al. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707568 · Cited by 140
Cannabinoid Type-1 Receptor Reduces Pain and Neurotoxicity Produced by Chemotherapy
Khasabova, I. A., Khasabov, S., Paz, J., Harding-Rose, C., Simone, D. A., & Seybold, V. S. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0403-12.2012 · Cited by 129
“AM630 has 165-fold greater affinity at CB2 compared with CB1 receptors (Ross et al., 1999).”
BackgroundGuindon, J., & Beaulieu, P. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.12.002 · Cited by 90
Da Fonseca Pacheco, D., Klein, A., De Castro Perez, A., Da Fonseca Pacheco, C. M., De Francischi, J. N., & Duarte, I. D. G. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.175 · Cited by 81
Naguib, M., Diaz, P., Xu, J. J., Astruc‐Diaz, F., Craig, S., Vivas‐Mejia, P., & Brown, D. L. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.340 · Cited by 82
Gui, H., Liu, X., Wang, Z.-W., He, D.-Y., Su, D.-F., & Dai, S.-M. (2014) · Rheumatology · doi:10.1093/rheumatology/ket447 · Cited by 76
Dolles, D., Hoffmann, M., Gunesch, S., Marinelli, O., Möller, J., Santoni, G., Chatonnet, A., Lohse, M. J., Wittmann, H.-J., Strasser, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01760 · Cited by 67
JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy
Khasabova, I. A., Yao, X., Paz, J., Lewandowski, C. T., Lindberg, A. E., Coicou, L., Burlakova, N., Simone, D. A., & Seybold, V. S. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.09.008 · Cited by 50
Scheiner, M., Dolles, D., Gunesch, S., Hoffmann, M., Nabissi, M., Marinelli, O., Naldi, M., Bartolini, M., Petralla, S., Poeta, E., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00623 · Cited by 49
Cannabinoid receptor systems: therapeutic targets for tumour intervention.
Jones, S., & Howl, J. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.6.749 · Cited by 13
“CB2 antagonists comprise the diarylpyrazole, SR-144528 [37], and the aminoalkylindole, AM-630 [38].”
Background
Metadata
- Authors
- Ross, R. A., Brockie, H. C., Stevenson, L. A., Murphy, V. L., Templeton, F., Makriyannis, A., & Pertwee, R. G.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 1999-02
- Volume
- 126
- Issue
- 3
- Pages
- 665-672
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2062413775
- Cited by
- 404
- References
- 25
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.